An investigational drug for the treatment of the asbestos related cancer, mesothelioma, has entered into Phase II clinical trials, according to a recent report. It has been claimed that the new compound is able to inhibit the growth of cancer cells.

The announcement that the compound, which is known as CBP501, is entering into Phase II of clinical trials was made by the developers of the compound, biotech firm CanBas and Takeda Pharmaceutical Company Limited. It is thought that the compound could assist with the treatment of non-small cell lung cancer.

Earlier Phase I clinical trials have already been carried out on the compound, and it was found that the drug could increase anti-cancer cell activity, and when given with other treatments could speed up the death of cancer cells.

In November of last year the development companies also carried out a separate clinical trial with the compound, assessing it for effectiveness in the treatment of the asbestos related cancer mesothelioma.

Be Sociable, Share!